Charles Schwab
ACRV icon

Charles Schwab’s Acrivon Therapeutics ACRV Stock Holding History

Charles Schwab’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-63,636
Closed -$75.7K – 3457
2025
Q2 		$75.7K Sell
63,636
-47,684
-43% -$65.4K ﹤0.01% 3427
2025
Q1 		$226K Sell
111,320
-2,520
-2% -$13.6K ﹤0.01% 3241
2024
Q4 		$685K Sell
113,840
-2,413
-2% -$17.5K ﹤0.01% 3044
2024
Q3 		$814K Sell
116,253
-27,705
-19% -$218K ﹤0.01% 2986
2024
Q2 		$835K Buy
143,958
+66,576
+86% +$536K ﹤0.01% 2999
2024
Q1 		$553K Buy
77,382
+8,881
+13% +$41.2K ﹤0.01% 2982
2023
Q4 		$337K Buy
68,501
+840
+1% +$4.44K ﹤0.01% 3196
2023
Q3 		$647K Buy
67,661
+6,703
+11% +$77.4K ﹤0.01% 2950
2023
Q2 		$790K Buy
60,958
+2,749
+5% +$33.3K ﹤0.01% 2846
2023
Q1 		$739K Buy
+58,209
New +$977K ﹤0.01% 2832

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Charles Schwab's ACRV Position: Q3 2025 in Review

Charles Schwab sold out of Acrivon Therapeutics (ACRV) in Q3 2025, closing a stake of 63,636 shares — an estimated $75.7K sold.

Charles Schwab first reported a position in ACRV in Q1 2023 and held it in 10 quarters. The position peaked at $835K in Q2 2024. 48 funds tracked by Wall St. Rank hold ACRV as of Q3 2025.

  • Charles Schwab reported no remaining Acrivon Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 63,636 Acrivon Therapeutics shares in Q3 2025, an estimated $75.7K.
  • Charles Schwab first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 10 quarters.
  • Charles Schwab's Acrivon Therapeutics position peaked at $835K in Q2 2024.
  • 48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.